Pre-clinical pharmacokinetics evaluation of an anticonvulsant candidate benzaldehyde semicarbazone free and included in β-cyclodextrin

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 5, 2010, Pages 355-362

  Kaiser, Moacir ^a   Azeredo, Francine Johansson ^a   Uchôa, Flávia De Toni ^a   Beraldo, Heloísa de Oliveira ^b   Dalla Costa, Teresa ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anticonvulsant; Benzaldehyde semicarbazone; Cyclodextrin; Pharmacokinetics; Plasma protein binding; Tissue distribution

Indexed keywords

ANTICONVULSIVE AGENT; BENZALDEHYDE SEMICARBAZONE; BENZALDEHYDE SEMICARBAZONE BETA CYCLODEXTRIN COMPLEX; CENTRAL DEPRESSANT AGENT; DRUG CARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ULTRAVIOLET RADIATION;

ANIMALS; ANTICONVULSANTS; BETA-CYCLODEXTRINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; MALE; RATS; RATS, WISTAR; SEMICARBAZONES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 77549087159     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.01.003     Document Type: Article

References (22)

1. Beraldo H., Sinistera R.D., Teixeira L.R., Vieira R.P., and Doretto M.C. An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-β-cyclodextrin and benzaldehyde semicarbazone. Bioche. Biophys. Res. Commun. 296 (2002) 241-246
2. Bianchi M., Rossoni G., Sacerdote P., Panerai A.E., and Berti F. Carbamazepine exerts anti-inflammatory effects in the rat. Eur. J. Pharmacol. 294 (1995) 71-74
3. Dietzel K., Estes K.S., Brewster M.E., Bodor N.S., and Derendorf H. The use of 2-hydroxypropyl-β-cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs. Int. J. Pharm. 59 (1990) 225-230
4. Dimmock J.R., Sidhu K.K., Thayer R.S., Mack P., Duffy M.J., Reid R.S., Quail J.W., Pugazhenthi U., Ong A., Bikker J.A., and Weaver D.F. Anticonvulsants activities of some aryl semicarbazones displaying potent oral activity in the maximal electroshock screen in rats accompanied by high protection indices. J. Med. Chem. 36 (1993) 2243-2252
5. Dimmock J.R., Sidhu K.K., Tumber S.D., Basran S.K., Chen M., Quail J.W., Yang J., Rozas I., and Weaver D.F. Some aryl semicarbazones possessing anticonvulsant activities. Eur. J. Med. Chem. 30 (1995) 287-301
6. Dimmock J.R., Vashishtha S.C., and Stables J.P. Anticonvulsant properties of various acetylhydrazones, oxamoylhydrazones and semicarbazones derived from aromatic and unsaturated carbonyl compounds. Eur. J. Med. Chem. 35 (2000) 241-248
7. 11C]toluene. Nucl. Med. Biol. 29 (2002) 607-612
8. Ilyin V.I., Hodges D.D., Whittemore E.R., Carter R.B., Cai S.X., and Woodward R.M. V102862 (Co 102862): a potent, broad-spectrum state-dependent blocker of mammalian voltage-gated sodium channels. Br. J. Pharmacol. 144 (2005) 801-812
9. Irie T., and Uekama K. Pharmaceutical applications of ciclodextrins. III. Toxicological issues and safety evaluations. J. Pharm. Sci. 86 (1997) 147-162
10. Jeulin H., Venard V., Carapito D., Finance C., and Kedzierewicz F. Effective ribavirin concentration in mice brain using cyclodextrin as a drug carrier: evaluation in a measles encephalitis model. Antiviral Res. 81 (2009) 261-266
11. Kaiser M., Azeredo F.J., Beraldo H., and Dalla Costa T. Development and validation of a HPLC-UV method for the quantification of benzaldehyde semicarbazone in rat plasma: a new anticonvulsant prototype. COLACRO XII, Florianópolis, Brazil (2008)
12. Mccorry d., Chadwick d., and Marson a. Current drug treatment of epilepsy in adults. Lancet Neurol. 3 (2004) 729-735
13. Monnaert V., Tilloy S., Bricout H., Fenart L., Cecchelli R., and Monflier E. Behavior of α-, β-, and γ-ciclodextrins and their derivatives on an in vitro model of blood-brain barrier. J. Pharmacol. Exp. Ther. 310 (2004) 745-751
14. Nakanishi N., Nadai T., Masada N., and Miyagima K. Effect of cyclodextrins on biological membranes. II. Mechanism of enhancement on the intestinal absorption of non-absorbable drug by cyclodextrins. Chem. Pharma. Bull. 40 (1992) 1252-1256
15. Rocha T.T.S., Costa K.A., Oliveira A.C.P., Nascimento Jr. E.B., Bertollo C.M., Teixeira L.R., Beraldo H., and Coelho M.M. Antinociceptive, antiedematogenic and antiangiogenic effects of benzaldehyde semicarbazone. Life Sci. 79 (2006) 499-505
16. Shargel L., Wu-Pong S., and Yu A.B.C. Applied Biopharmaceutics & Pharmacokinetics (2005), McGran-Hill, New York pp. 52-184
17. Teixeira L.R., Sinisterra R.D., Vieira R.P., Doretto M.C., and Beraldo H. Inclusion of benzaldehyde semicarbazone into β-cyclodextrin produces a very effective anticonvulsant formulation. J. Incl. Phenom. Macr. 47 (2003) 77-82
18. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharma. Bull. 52 (2004) 900-915
19. WHO, 2001a. The global campaign against epilepsy. Information pack for the launch of the global campaign's second phase, 12-13 February 2002. http://www.who.int.
20. WHO, 2001b. Epilepsy: aetiogy, epidemiology and prognosis. http://www.who.int.
21. Yancey P.G., Rodrigueza W.V., Kilsdonk E.P.C., Stoudt G.W., Johnson W.J., Phillips M.C., and Rothblat G.H. Cellular cholesterol efflux mediated by cyclodextrins: demonstration of kinetic pools and mechanism of efflux. J. Biol. Chem. 271 (1996) 16026-16034
22. Yogeeswari P., Sriram D., Thirumurugan R., Raghavendran J.V., Sudhan K., Pavana R.K., and Stables J. Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design. J. Med. Chem. 48 (2005) 6202-6211